about
Pharmacological interventions for reducing weight gain in schizophreniaThe long-term effect of energy restricted diets for treating obesityNaltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to dateNext generation of weight management medications: implications for diabetes and CVD riskRegulation of obesity and insulin resistance by nitric oxideObesity and outpatient rehabilitation using mobile technologies: the potential mHealth approach.Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptorLorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial.Antiobesity strategy targets energy economy safeguards.Obesity Education Strategies for Cancer Prevention in Women's Health.Inequalities in access to bariatric surgery in CanadaIntestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity.Fatty Acid Transport Proteins: Targeting FATP2 as a Gatekeeper Involved in the Transport of Exogenous Fatty Acids.Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.Peripheral targets in obesity treatment: a comprehensive update.Anti-obesity activity of hen egg anti-lipase immunoglobulin yolk, a novel pancreatic lipase inhibitor.Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.Ginsenoside Rg1 inhibits dietary-induced obesity and improves obesity-related glucose metabolic disorders.
P2860
Q24194410-2BEB6B37-13A0-41F5-88A6-FD1F70E6B1A6Q26801142-013F06B4-64E4-42F5-B658-7EC68EED8DDAQ27014110-4161FC73-5A64-4942-9CDC-B1C4C528F939Q28082858-A52A150E-E741-42F2-9BBB-E3F0293243A5Q30363035-85346DD7-E916-4649-A35C-355C0CD6D25FQ33732117-C6DF682E-51E3-4F92-97B9-7E9FA5406FF2Q33838127-45245BE5-F68B-4BF9-89C1-2FEE050BA134Q34533195-54917C32-F00E-4A88-9807-2BE1AB88C927Q35399304-E5DE28A2-C462-4939-BEAF-2BF50D94E7EDQ36567721-36A5E7C9-5700-4320-93A5-5375F2BB7375Q36673590-37225758-3911-45D3-BA88-E82DBF5590FCQ36694416-C1E07C0A-9595-44C5-A501-685E827CFC03Q37102291-B0857806-96C7-4ED8-9652-1B73BAEF6389Q37348394-3BD55B06-82DC-426A-8BC2-9E9216D44621Q37589010-4FD4AB52-DFE6-41F9-B63C-F45BED4A1D25Q38194649-7F2B2091-750D-4C1D-BE0F-399B53BDC0DDQ39818185-19EE4EA8-A2CF-4F24-99D7-0FF4045B3262Q42004480-10694F5A-0744-4BF6-8598-E869535CD8EDQ51245851-961FFFBC-317B-44AE-8132-0C9373A0CF5E
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
New pharmacological approaches for obesity management.
@ast
New pharmacological approaches for obesity management.
@en
New pharmacological approaches for obesity management.
@nl
type
label
New pharmacological approaches for obesity management.
@ast
New pharmacological approaches for obesity management.
@en
New pharmacological approaches for obesity management.
@nl
prefLabel
New pharmacological approaches for obesity management.
@ast
New pharmacological approaches for obesity management.
@en
New pharmacological approaches for obesity management.
@nl
P2860
P356
P1476
New pharmacological approaches for obesity management
@en
P2093
Arya M Sharma
P2860
P2888
P304
P356
10.1038/NRENDO.2013.113
P577
2013-06-11T00:00:00Z